In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Cyclacel Pharmaceuticals, Inc.. Trade Record

NASDAQ:CYCC Cyclacel Pharmaceuticals, Inc. stock gains 8.99% Exit Nov 29, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart CYCC Nov 15, 2017, priceSeries
About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; in Phase II clinical trial for myelodysplastic syndromes; and in Phase I/II clinical trial in combination with seliciclib, a drug candidate to treat solid tumors. Its oncology development programs also comprise Seliciclib, an oral inhibitor of cyclin dependent kinase (CDK) 2/9 enzymes, which are central to the process of cell division and cell cycle control that has completed a Phase IIb clinical trial; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial targeting CDK2/9 enzymes with potential utility in hematological malignancies and solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage; and Aurora Kinase inhibitors, a serine/threonine protein kinases that focuses on cell division or mitosis for the treatment of cancer. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Trade Information
Trade Type
Entry Date
Nov 15, 2017
Entry Price
Sell Date
Nov 29, 2017
Sell Price
Net Gain
Hold Time
9 Trading Days